TASER Reports 2016 Third Quarter Results

Nov. 16, 2016
Record Revenues of $71.9 million, Up 43% Year-Over-Year

SCOTTSDALE, Ariz., Nov. 9, 2016 /PRNewswire/ -- TASER International (NASDAQ: TASR), today reported financial results for the third quarter ended September 30, 2016.

"I am simply delighted with the results of our team's extraordinary work this part quarter. We realized strong growth in the period from both our Weapons and Axon businesses, and our Axon bookings remained strong," commented Rick Smith, TASER CEO and Founder. "Customers value the Axon network we have created, which now connects over half of the major cities in the United States, bringing the criminal justice system online with advanced technology and enhanced transparency. We will continue to grow our existing platform offerings while developing complementary capabilities to extend our leadership position with law enforcement around the world."

Third Quarter 2016 Financial Highlights:

  • Net sales increased 43% to $71.9 million in the third quarter of 2016 compared to $50.4 million in the third quarter of 2015. International sales were $11.3 million in the third quarter of 2016.
  • TASER Weapons segment revenues increased 34% to $52.9 million in the third quarter of 2016 compared to $39.5 million in the third quarter of 2015.
  • Axon segment revenues increased 75% to $18.9 million in the third quarter of 2016 compared to $10.9 million in the third quarter of 2015.
  • Consolidated gross margin was 65% in the third quarter of 2016 compared to 62% in the third quarter of 2015.
  • TASER Weapons segment gross margin was 72% in third quarter 2016 compared to 69% in the third quarter of 2015.
  • Axon segment gross margins increased to 45% in the third quarter of 2016 compared to 37% in the third quarter of 2015. Axon service margins increased to 81% in the third quarter of 2016 compared to 67% in the third quarter of 2015. Axon hardware product margins (excluding Axon services) decreased to 15% in the third quarter 2016 compared to 25% in the third quarter of 2015.
  • Sales, general and administrative (SG&A) expenses of $28.1 million in the third quarter of 2016 increased $10.3 million, from $17.8 million in the third quarter of 2015. The increase is primarily due to increased headcount, expenses related to international expansion, professional/consulting fees, legal costs, and higher variable compensation.
  • Research and development (R&D) expenses of $7.4 million for the third quarter of 2016 increased $0.8 million when compared to the third quarter of 2015. The increase is primarily related to increased headcount.
  • Income from operations was $11.1 million in the third quarter of 2016 compared to $6.7 million in the third quarter of 2015.
  • Income tax expense in the quarter was $6.8 million for an effective tax rate of 63.9%.  We were adversely affected by losses in foreign entities from which we do not currently expect to receive a tax benefit.  Additionally, we recognized an unfavorable provision to tax return true up relating to our 2015 tax return filed in September of $0.4 million. The combined impact of the foreign entity losses which we do not currently expect to receive a tax benefit from and the return to provision true up is approximately $1.5 million or $0.03 cents per share.
  • Net income for the third quarter of 2016 was $3.8 million, or $0.07 per diluted share, compared to $1.5 million, or $0.03 per diluted share, in the third quarter of 2015.
  • Adjusted EBITDA for the third quarter of 2016 was $13.8 million compared to $9.5 million in the third quarter of 2015.
  • In the third quarter of 2016, the Company generated $11.6 million in cash from operating activities. Cash, cash equivalents and investments were $102.5 million at September 30, 2016, compared to $118.3 million at December 31, 2015. Included in these balances were $6.3 million and $8.5 million in long-term investments as of September 30, 2016 and December 31, 2015, respectively.

Business Highlights:

  • As of the end of the third quarter of 2016, 35 of the 68 U.S. major city law enforcement agencies have purchased TASER's Axon body-worn cameras and/or its digital evidence management solution: Albuquerque, Atlanta, Baltimore, Baltimore County, Charlotte-Mecklenburg, Chicago, Cincinnati, Cleveland, Dallas, Denver, Fort Worth, Fresno, Kansas City, Los Angeles, Las Vegas, Louisville, Memphis, Mesa, Miami, Milwaukee, Minneapolis, Montgomery County, New Orleans, Omaha, Philadelphia, Pittsburgh, Salt Lake City, San Antonio, San Diego, San Francisco, San Jose, Tampa, Tucson, Washington, DC, and Wichita.
  • Axon platform user count continued to grow, extending the Company's market leadership. During the three months ended September 30, 2016, the Company booked approximately 15,600 seats on its digital evidence management platform, Evidence.com, net of renewals. Since inception, the Company has booked cumulative Evidence.com licenses of approximately 110,600.

CFO Transition

TASER also announced today that following a transition period, CFO Dan Behrendt will be leaving the Company to pursue other opportunities. Mr. Behrendt will remain with TASER in his current capacity through the filing of the Company's Form 10-K to help ensure an orderly transition of his responsibilities. The Company has commenced a national search for a new Chief Financial Officer.

"Dan has been an integral part of TASER's success since joining 12 years ago," said Mr. Smith. "He has brought strong financial leadership to the organization, most notably as we've broadened our law enforcement solutions capabilities to include our Axon-branded, cloud-connected device platform. We thank Dan for his many contributions to TASER during his tenure and for the positive impact he has had on our organization."

Mr. Behrendt commented, "I am grateful for the opportunity to serve as part of the leadership team at TASER, and I am confident that we have built a solid foundation for future growth. We've made considerable progress over the last several years, and I'm particularly proud of the finance organization and team we've put in place. After more than a decade with TASER and following an orderly transition period, I'll look forward to pursuing new endeavors."

Quarterly Conference Call:

The Company will host its third quarter 2016 earnings conference call on Wednesday, November 9, 2016 at 4:30 p.m. ET. To join the live audio presentation, please dial toll free 877-303-9126, or for international callers, please dial +1-253-237-1156. The passcode is 56350705.

The Company has posted supplemental materials including its key operating metrics on its website to provide additional information about our third quarter financial results.

The Company plans to update and post its investor relations presentation to http://investor.taser.com within the next two weeks with the third quarter results. Archived presentations from previous quarters can also be found on the website.

Statistical Definitions:

Axon cameras and Evidence.com bookings represent a statistical measure defined as the sales price of orders placed in the relevant time period. Bookings are an indication of the activity the Company is seeing relative to Axon cameras and Evidence.com. We consider bookings to be a statistical measure defined as the sales price of orders (not invoiced sales) placed in the relevant fiscal period, net of cancellations, regardless of when the products or services ultimately will be provided. Some bookings might be invoiced in subsequent years.

Due to municipal government funding rules, certain of the future year amounts included in bookings are subject to budget appropriation or other contract cancellation clauses. Although TASER has entered into contracts for the delivery of products and services in the future and anticipates the contracts will be completed, if agencies invoke a cancellation clause or do not appropriate funds in future year budgets, revenue associated with these bookings will ultimately not be recognized, resulting in a future reduction to bookings. In the third quarter of 2016, there was approximately $107,000 in reversals related to prior period bookings due to non-appropriation or other cancellation reasons.

For more information relative to our revenue recognition policies, please reference our SEC filings.

Non-GAAP Measures:

To supplement the Company's financial results presented in accordance with GAAP, we present the non-GAAP financial measures of EBITDA, Adjusted EBITDA and Free Cash Flow. Our management uses these non-GAAP financial measures in evaluating the Company's performance in comparison to prior periods. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance, and when planning and forecasting our future periods. A reconciliation of GAAP to the non-GAAP financial measures is presented at the end of the release.

EBITDA is defined as consolidated net income before interest expense, income taxes and depreciation and amortization. Adjusted EBITDA, as presented herein, is defined as EBITDA before certain other items, including: stock-based compensation; net gain/loss on write-down/disposal of property, equipment and intangible assets; and loss on impairment.

Free Cash Flow is defined as cash flows provided by operating activities minus purchases of property, plant and equipment and intangible assets.

Caution on Use of Non-GAAP Measures

Although these non-GAAP financial measures are not consistent with GAAP, management believes investors will benefit by referring to these non-GAAP financial measures when assessing the Company's operating results, as well as when forecasting and analyzing future periods. However, management recognizes that:

  • these non-GAAP financial measures are limited in their usefulness and should be considered only as a supplement to the Company's GAAP financial measures;
  • these non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Company's GAAP financial measures;
  • these non-GAAP financial measures should not be considered to be superior to the Company's GAAP financial measures; and
  • these non-GAAP financial measures were not prepared in accordance with GAAP and investors should not assume that the non-GAAP financial measures presented in this earnings release were prepared under a comprehensive set of rules or principles.

Further, these non-GAAP financial measures may be unique to the Company, as they may be different from similarly titled non-GAAP financial measures used by other companies. As such, this presentation of non-GAAP financial measures may not enhance the comparability of the Company's results to the results of other companies.

About TASER International, Inc.

TASER International makes communities safer with innovative public safety technologies. Founded in 1993, TASER first transformed law enforcement with its electrical weapons. TASER continues to define smarter policing with its growing suite of technology solutions, including Axon body-worn video cameras and Evidence.com, a secure digital evidence management platform. More than 174,000 lives saved from death or serious injury and countless dollars have been saved with TASER's products and services.

Learn more at www.taser.com and www.axion.io or by calling (800) 978-2737.

TASER® and Axon® are registered trademarks of TASER International, Inc., registered in the U.S. All rights reserved. TASER logo, Axon, Axon Body, Axon Body 2, Axon Flex, Axon Interview, Axon Signal, TASER X26, TASER X26P, TASER CAM and TASER X2 are trademarks of TASER International, Inc. All rights are reserved for trademarks of TASER International, Inc.

Note to Investors

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements regarding our expectations, beliefs, intentions or strategies regarding the future. We intend that such forward-looking statements be subject to the safe-harbor provided by the Private Securities Litigation Reform Act of 1995. The forward-looking information is based upon current information and expectations regarding TASER International, Inc. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. TASER International assumes no obligation to update the information contained in this press release, except as required by law.

We caution that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward looking statements herein. Such factors include, but are not limited to: the adverse effect of the United Kingdom's exit from the European Union; market acceptance of our products; our dependence on sales of our TASER X26P and X2 CEWs; our ability to design, introduce and sell new products; delays in development schedules; rapid technological change and competition; product defects; breach of our security measures resulting in unauthorized access to customer data; outages and disruptions relating to our Evidence.com service; budgetary and political constraints of prospects and customers; the length of our sales cycle and our ability to realize benefits from our marketing and selling efforts; our exposure to cancellations of government contracts due to appropriation clauses; changes in civil forfeiture laws; the long-term revenue recognition cycle for our SaaS Evidence.com product; our reliance on third party cloud-based storage providers; litigation risks resulting from alleged product-related injuries and media publicity concerning allegations of deaths occurring after use of the TASER device and the negative impact this publicity could have on sales; the outcome of pending or future litigation; our ability to protect our intellectual property as well as intellectual property infringement claims and relating litigation costs; our successful identification of existing intellectual property rights that might infringe on our developments; competition in foreign countries relating to our inability to protect our patents; risks of governmental regulations, including regulations of our products by the United States Consumer Product Safety Commission, regulation of our products as a "crime control" product by the Federal government, state and local government regulation and foreign regulation and the adverse effects that could result from our products being classified as firearms by the United States Bureau of Alcohol and Firearms; regulatory and political challenges presented by international markets; our compliance with regulations governing the environment, including but not limited to, regulations within the European Union; regulations relating to voice, data and communications services; regulations relating to conflict minerals; our dependence on third party suppliers for key components of our products; component shortages; rising costs of raw materials and transportation relating to petroleum prices; that we may experience declines in gross margins due to a shift in product sales from conducted electrical weapons to Axon devices; our ability to manage our growth and increase manufacturing production to meet demand; establishment and expansion of our direct and indirect distribution channels; our ability to pursue sales directly with customers; risks relating to acquisitions and joint ventures; goodwill impairment; catastrophic events; quarterly fluctuations in our operating results; the adverse effects on our operations and financial results from foreign currency fluctuations; fluctuations in our effective tax rate; counter-party risks relating to cash balances held in excess of FDIC insurance limits; employee retention risks; volatility in our stock price; and other factors identified in documents filed by us with the Securities and Exchange Commission, including those set forth in our Form 10-K for the year ended December 31, 2015 and Forms 10-Q for the quarters ended March 31, 2016 and June 30, 2016.

Please visit http://investor.taser.com, www.twitter.com/officialtaser, www.twitter.com/axontechnology and www.facebook.com/TASER.International where TASER discloses information from time to time about the company, its financial information, and its business.

For investor relations information please contact Arvind Bobra via email at [email protected].

CONTACT: Arvind Bobra
Investor Relations
TASER International, Inc.
[email protected]

TASER INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)

 
 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2016

 

2015

 

2016

 

2015

               

Net sales

$

71,882

   

$

50,376

   

$

186,168

   

$

141,851

 

Cost of products sold and services delivered

25,317

   

19,308

   

65,402

   

50,192

 

Gross margin

46,565

   

31,068

   

120,766

   

91,659

 

Operating expenses:

             

Sales, general and administrative

28,121

   

17,834

   

77,333

   

47,842

 

Research and development

7,358

   

6,528

   

20,995

   

16,992

 

Total operating expenses

35,479

   

24,362

   

98,328

   

64,834

 

Income from operations

11,086

   

6,706

   

22,438

   

26,825

 

Interest income and other (expense) income, net

(455)

   

(22)

   

(460)

   

12

 

Income before provision for income taxes

10,631

   

6,684

   

21,978

   

26,837

 

Provision for income taxes

6,788

   

5,163

   

11,022

   

12,008

 

Net income

$

3,843

   

$

1,521

   

$

10,956

   

$

14,829

 

Net income per common and common equivalent shares:

             

Basic

$

0.07

   

$

0.03

   

$

0.21

   

$

0.28

 

Diluted

$

0.07

   

$

0.03

   

$

0.20

   

$

0.27

 

Weighted average number of common and common equivalent shares outstanding:

             

Basic

52,206

   

53,709

   

52,791

   

53,509

 

Diluted

53,141

   

54,691

   

53,656

   

54,671

 

TASER INTERNATIONAL, INC.

SEGMENT REPORTING

(Unaudited)

(dollars in thousands)

 
 

Three Months Ended September 30, 2016

 

Three Months Ended September 30, 2015

 

TASER
Weapons

 

Axon

 

Total

 

TASER
Weapons

 

Axon

 

Total

                       

Product sales

$

52,938

   

$

10,266

   

$

63,204

   

$

39,520

   

$

7,745

   

$

47,265

 

Service revenue

   

8,678

   

8,678

   

   

3,111

   

3,111

 

Net sales

52,938

   

18,944

   

71,882

   

39,520

   

10,856

   

50,376

 

Cost of products sold

14,973

   

8,691

   

23,664

   

12,445

   

5,829

   

18,274

 

Cost of services delivered

   

1,653

   

1,653

   

   

1,034

   

1,034

 

Gross margin

37,965

   

8,600

   

46,565

   

27,075

   

3,993

   

31,068

 

Sales, general and administrative

16,439

   

11,682

   

28,121

   

11,941

   

5,893

   

17,834

 

Research and development

1,408

   

5,950

   

7,358

   

1,151

   

5,377

   

6,528

 

Income (loss) from operations

$

20,118

   

$

(9,032)

   

$

11,086

   

$

13,983

   

$

(7,277)

   

$

6,706

 
                       

Gross margin %

71.7

%

 

45.4

%

 

64.8

%

 

68.5

%

 

36.8

%

 

61.7

%

Operating margin %

38.0

%

 

(47.7)

%

 

15.4

%

 

35.4

%

 

(67.0)

%

 

13.3

%

                                   
                                   
 

Nine Months Ended September 30, 2016

 

Nine Months Ended September 30, 2015

 

TASER
Weapons

 

Axon

 

Total

 

TASER
Weapons

 

Axon

 

Total

                       

Product sales

$

144,307

   

$

23,438

   

$

167,745

   

$

115,686

   

$

18,177

   

$

133,863

 

Service revenue

   

18,423

   

18,423

   

   

7,988

   

7,988

 

Net sales

144,307

   

41,861

   

186,168

   

115,686

   

26,165

   

141,851

 

Cost of products sold

43,998

   

17,174

   

61,172

   

34,805

   

12,692

   

47,497

 

Cost of services delivered

   

4,230

   

4,230

   

   

2,695

   

2,695

 

Gross margin

100,309

   

20,457

   

120,766

   

80,881

   

10,778

   

91,659

 

Sales, general and administrative

46,395

   

30,938

   

77,333

   

33,469

   

14,373

   

47,842

 

Research and development

3,773

   

17,222

   

20,995

   

3,418

   

13,574

   

16,992

 

Income (loss) from operations

$

50,141

   

$

(27,703)

   

$

22,438

   

$

43,994

   

$

(17,169)

   

$

26,825

 
                       

Gross margin %

69.5

%

 

48.9

%

 

64.9

%

 

69.9

%

 

41.2

%

 

64.6

%

Operating margin %

34.7

%

 

(66.2)

%

 

12.1

%

 

38.0

%

 

(65.6)

%

 

18.9

%

TASER INTERNATIONAL, INC.

Axon and Evidence.com Bookings by Quarter

(Unaudited)

(in thousands)

 
 

September 30, 2016

 

June 30, 2016

 

March 31, 2016

 

December 31, 2015

 

September 30, 2015

                   

Bookings

$

57,491

   

$

72,034

   

$

52,059

   

$

44,668

   

$

36,877

 
                                       

Axon and Evidence.com Future Contracted Revenue

(Unaudited)

(in thousands)

 
 

September 30,
2016

 

June 30, 2016

Cumulative bookings, net of cancellations

$

392,070

   

$

334,579

 

Cumulative Axon & Evidence.com recognized revenue

(90,047)

   

(71,799)

 

Future contracted revenue

$

302,023

   

$

262,780

 

Axon and Evidence.com future contracted revenue represent a statistical measure defined as cumulative bookings for Axon and Evidence.com minus cumulative recognized revenue related solely to Axon and Evidence.com. Future contracted revenues are an indication of momentum of longer-term contracts being signed and the expectations of future revenues in the Axon segment.  Cumulative Axon & Evidence.com recognized revenue is presented as the Axon segment revenues exclusive of TASER Cam recorder revenues.

TASER INTERNATIONAL, INC.

UNIT SALES STATISTICS

(Unaudited)

Units in whole number

 
 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2016

 

2015

 

Unit
Change

 

Percent
Change

 

2016

 

2015

 

Unit
Change

 

Percent
Change

                               

TASER X26P

23,259

   

13,659

   

9,600

   

70.3

%

 

58,385

   

45,946

   

12,439

   

27.1

%

TASER X2

12,481

   

8,036

   

4,445

   

55.3

   

34,697

   

25,510

   

9,187

   

36.0

 

TASER X26

365

   

818

   

(453)

   

(55.4)

   

1,886

   

4,341

   

(2,455)

   

(56.6)

 

TASER Pulse and Bolt

1,936

   

1,801

   

135

   

7.5

   

6,522

   

5,785

   

737

   

12.7

 

Cartridges

544,671

   

435,237

   

109,434

   

25.1

   

1,424,656

   

1,189,118

   

235,538

   

19.8

 

Axon Flex

4,961

   

6,759

   

(1,798)

   

(26.6)

   

11,026

   

15,921

   

(4,895)

   

(30.7)

 

Axon Body

25,093

   

4,778

   

20,315

   

425.2

   

40,977

   

15,381

   

25,596

   

166.4

 

E-Dock

6,432

   

2,075

   

4,357

   

210.0

   

11,236

   

5,554

   

5,682

   

102.3

 

TASER Cam

1,323

   

2,887

   

(1,564)

   

(54.2)

   

6,460

   

8,993

   

(2,533)

   

(28.2)

 

TASER INTERNATIONAL, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(Unaudited)

Dollars in thousands

 
 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2016

 

2015

 

2016

 

2015

               

Net income

$

3,843

   

$

1,521

   

$

10,956

   

$

14,829

 

   Depreciation and amortization

901

   

948

   

2,744

   

2,310

 

   Interest expense, net

   

8

   

10

   

9

 

   Provision for income taxes

6,788

   

5,163

   

11,022

   

12,008

 

EBITDA

$

11,532

   

$

7,640

   

$

24,732

   

$

29,156

 
               

Adjustments:

             

Stock-based compensation expense

$

2,216

   

$

1,863

   

$

6,742

   

$

5,086

 

Net loss on disposal of property, equipment and intangible assets, net

64

   

38

   

61

   

203

 

Adjusted EBITDA

$

13,812

   

$

9,541

   

$

31,535

   

$

34,445

 

Adjusted EBITDA as a percentage of net sales

19.2

%

 

18.9

%

 

16.9

%

 

24.3

%

               

Composition of stock-based compensation:

 
 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2016

 

2015

 

2016

 

2015

               

Cost of products sold and services delivered

$

77

   

$

118

   

$

247

   

$

276

 

Sales, general and administrative

1,348

   

1,123

   

4,197

   

2,982

 

Research and development

791

   

622

   

2,298

   

1,828

 
 

$

2,216

   

$

1,863

   

$

6,742

   

$

5,086

 

TASER INTERNATIONAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

 
 

September 30, 2016

 

December 31, 2015

 

(Unaudited)

   

ASSETS

Current Assets:

     

Cash and cash equivalents

$

50,600

   

$

59,526

 

Short-term investments

45,620

   

50,254

 

Accounts and notes receivable, net

32,858

   

27,701

 

Inventory, net

25,503

   

15,763

 

Prepaid expenses and other current assets

13,867

   

8,165

 

Total current assets

168,448

   

161,409

 
       

Property and equipment, net

22,976

   

21,848

 

Deferred income tax assets, net

16,753

   

13,719

 

Intangible assets, net

7,116

   

7,588

 

Goodwill

8,885

   

9,596

 

Long-term investments

6,260

   

8,525

 

Other assets

21,762

   

7,196

 

Total assets

$

252,200

   

$

229,881

 
       

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

     

Accounts payable

$

8,982

   

$

7,333

 

Accrued liabilities

16,086

   

8,643

 

Current portion of deferred revenue

41,284

   

20,851

 

Customer deposits

1,367

   

1,226

 

Current portion of debt and capital lease payable

51

   

87

 

Total current liabilities

67,770

   

38,140

 
       

Deferred revenue, net of current portion

35,968

   

30,190

 

Liability for unrecognized tax benefits

1,332

   

1,315

 

Long-term deferred compensation

3,111

   

2,199

 

Long-term contingent consideration

   

952

 

Other long-term liabilities

2,691

   

81

 

Total liabilities

110,872

   

72,877

 
       

Stockholders' Equity:

     

Preferred stock

   

 

Common stock

1

   

1

 

Additional paid-in capital

184,937

   

178,143

 

Treasury stock

(155,947)

   

(122,201)

 

Retained earnings

111,934

   

100,978

 

Accumulated other comprehensive income

403

   

83

 

Total stockholders' equity

141,328

   

157,004

 

Total liabilities and stockholders' equity

$

252,200

   

$

229,881

 

TASER INTERNATIONAL, INC.

SELECTED CASH FLOW INFORMATION

(Unaudited)

(in thousands)

 
 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2016

 

2015

 

2016

 

2015

               

Net income

$

3,843

   

$

1,521

   

$

10,956

   

$

14,829

 

Depreciation and amortization

901

   

948

   

2,744

   

2,310

 

Stock-based compensation

2,216

   

1,863

   

6,742

   

5,086

 

Net cash provided by operating activities

11,623

   

19,345

   

21,959

   

30,314

 

Net cash provided by (used in) investing activities

639

   

(6,097)

   

2,285

   

(33,293)

 

Net cash provided by (used in) financing activities

719

   

(7,704)

   

(33,801)

   

429

 

Cash and cash equivalents, end of period

50,600

   

45,887

   

50,600

   

45,887

 
               
               
 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2016

 

2015

 

2016

 

2015

               

Net cash provided by operating activities

$

11,623

   

$

19,345

   

$

21,959

   

$

30,314

 

Purchases of property and equipment

(1,371)

   

(2,069)

   

(3,335)

   

(3,839)

 

Purchases of intangible assets

(154)

   

(201)

   

(339)

   

(402)

 

Purchase of property and equipment and intangible assets in connection with business acquisition

   

(3,005)

   

   

(12,804)

 

Free cash flow, a non-GAAP measure

$

10,098

   

$

14,070

   

$

18,285

   

$

13,269

 

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of Officer, create an account today!

Request More Information

By clicking above, I agree to Endeavor Business Media's Terms of Service and consent to receive promotional communications from Endeavor, its affiliates, and partners per its Privacy Notice. I also understand my personal information will be shared with the sponsor of this content, who may contact me about their offerings per their privacy policy. I can unsubscribe anytime.